Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma

• Verfasst von: Stern, Martin [VerfasserIn]
• Verfasst von: Opelz, Gerhard [VerfasserIn]
• Verfasst von: Döhler, Bernd [VerfasserIn]
• Verfasst von: Hess, Christoph [VerfasserIn]
• Titel: Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma
• Verf.angabe: Martin Stern, Gerhard Opelz, Bernd Döhler, and Christoph Hess
• E-Jahr: 2010
• Jahr: March 5, 2010
• Umfang: 6 S.
• Fussnoten: Gesehen am 29.11.2023
• Titel Quelle: Enthalten in: Blood
• Ort Quelle: Washington, DC : American Society of Hematology, 1946
• Jahr Quelle: 2010
• Band/Heft Quelle: 115(2010), 19, Seite 3960-3965
• ISSN Quelle: 1528-0020
• DOI: doi:10.1182/blood-2009-10-250134
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1871599938

Abstract

Posttransplantation non-Hodgkin lymphoma is a life-threatening complication after transplantation. Although pharmacologically suppressed adaptive immunity plays a major role in its development, the role of innate immunity in posttransplantation lymphoma is unknown. We assessed the 158 V/F polymorphism in the Fc-γ receptor 3A gene (FCGR3A), killer cell immunoglobulin-like receptor (KIR) genotype, KIR ligand status, and a single nucleotide polymorphism affecting the production of interferon-γ (IFN-γ; +874 A/T) in 236 patients with posttransplantation lymphoma reported to the Collaborative Transplant Study. In addition, polymorphisms in the interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) genes previously associated with lymphoma development were also typed. Using a split-cohort approach, gene/allele frequency was related to the 5-year patient survival after the diagnosis of lymphoma and compared with 100 control solid organ transplant recipients. FCGR3A and KIR genotype significantly influenced survival after diagnosis of posttransplantation lymphoma: the hazard of dying was reduced in homozygous carriers of the high-affinity V allele (hazard ratio 0.49, 95% confidence interval 0.29-0.82, P = .006), whereas carrying a genotype including KIR2DL2/KIR2DS2 increased the risk of dying (hazard ratio 1.49, 95% confidence interval 1.07-2.05, P = .02). KIR ligands and cytokine polymorphisms had no effect on survival. None of the genetic loci analyzed emerged as risk factors for lymphoma development.